New drug aims to fix anemia after stem cell transplants

NCT ID NCT07362095

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests a drug called luspatercept (Reblozyl) to treat anemia in 46 people with acute leukemia who have had a stem cell transplant. The drug is given as a shot one and four weeks after transplant. The main goal is to see if it raises hemoglobin levels and reduces the need for blood transfusions. Researchers will also watch for side effects like infections or graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept (Reblozyl)
What this could lead to: If it works, this could offer a new way to treat anemia after stem cell transplant, reducing the need for blood transfusions and improving recovery.
What could go wrong: This is a very early, small study (46 people) with no comparison group. The drug may not improve hemoglobin levels, and risks like graft-versus-host disease or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA

Contacts and locations

Locations

Zhujiang Hospital
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.